Zhou Xuxiao, Yao Zhemin, Zheng Jing
Department of Urology, Yueqing People's Hospital, No.338 Qingyuan Road, Yueqing, Zhejiang, 325600, China.
Hormones (Athens). 2025 Sep 10. doi: 10.1007/s42000-025-00665-z.
This study aimed to evaluate the efficacy of combining levocarnitine with tadalafil in treating oligozoospermia and asthenozoospermia and to analyze its effects on serum sex hormone levels and sexual function.
A total of 80 patients diagnosed with oligozoospermia or asthenozoospermia at our hospital between March 2023 and February 2024 were randomly divided into two groups, A and B, with 40 patients each. Group A received levocarnitine combined with tadalafil, while Group B was administered levocarnitine alone. Both groups continued the regimen for 3 months. Parameters such as serum sex hormones [testosterone (T), luteinizing hormone (LH), follicle-stimulating hormone (FSH)], sexual function [assessed via the International Index of Erectile Function (IIEF)], and semen quality [including semen volume, sperm concentration, sperm viability, and progressive motility (PR)] were measured pre- and post-treatment. Efficacy rates and adverse reactions were also recorded and compared between the groups.
Post-treatment, both groups showed significant increases in serum T levels, all domains of IIEF scores (erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction), semen volume, sperm concentration, sperm viability, and PR (p < 0.001). Group A demonstrated significantly better results than Group B in all these parameters (p < 0.05). Differences in LH and FSH levels between the groups after treatment were not statistically significant (p > 0.05). The total efficacy rate was significantly higher in Group A (87.50%) compared to Group B (67.50%) (p < 0.05). Adverse reactions occurred in 10% of Group A and 5% of Group B, with no significant difference between the groups (p > 0.05).
The combination of levocarnitine and tadalafil shows significant efficacy and safety in treating oligozoospermia and asthenozoospermia, effectively enhancing serum testosterone levels, sexual function, and semen quality.
本研究旨在评估左卡尼汀联合他达拉非治疗少弱精子症的疗效,并分析其对血清性激素水平和性功能的影响。
选取2023年3月至2024年2月在我院诊断为少弱精子症的80例患者,随机分为A、B两组,每组40例。A组接受左卡尼汀联合他达拉非治疗,B组仅接受左卡尼汀治疗。两组均持续治疗3个月。治疗前后测量血清性激素[睾酮(T)、黄体生成素(LH)、卵泡刺激素(FSH)]、性功能[通过国际勃起功能指数(IIEF)评估]和精液质量[包括精液量、精子浓度、精子活力和前向运动率(PR)]等参数。记录并比较两组的有效率和不良反应。
治疗后,两组血清T水平、IIEF评分的所有领域(勃起功能、性高潮功能、性欲、性交满意度和总体满意度)、精液量、精子浓度、精子活力和PR均显著升高(p < 0.001)。A组在所有这些参数上的表现均显著优于B组(p < 0.